Alpheus Medical
Therapeutic approach for improving patient outcomes and reducing treatment burden
- Sector
- Biotech
- Headquarters
- CHANHASSEN, MN
- Founded
- 2014
- Latest Form D
- $34.5M, May 2025
- Total capital
- $55.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $55.5M
- 7 Form D · last May 2025
- 17 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 14
- 23 pending · first 2022
- Rank in peer group#122 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 7th filing$34.5M
- Private capital raisedForm D · SEC · 6th filing$14M
- Private capital raisedForm D · SEC · 5th filing$6M
- Private capital raisedForm D · SEC · 4th filing$50K
- Private capital raisedForm D · SEC · 3rd filing$643K
- Private capital raisedForm D · SEC · 2nd filing$100K
- Private capital raisedForm D · SEC · 1st filing$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#122 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Vijay AgarwalResearcherExecutive Officer, DirectorLinked by 12 patents
- Aaron SandoskiDirectorNamed in SEC Form D filings
- Conrad WangDirectorNamed in SEC Form D filings
- Imran EbaExecutive OfficerNamed in SEC Form D filings
- Jeremy LingExecutive OfficerNamed in SEC Form D filings
- Juan-Pablo MasDirectorNamed in SEC Form D filings
Show all 11 people
- Klaus VeitingerDirectorNamed in SEC Form D filings
- Peter ThompsonDirectorNamed in SEC Form D filings
- Robert SteinDirectorNamed in SEC Form D filings
- Steve WeinerExecutive OfficerNamed in SEC Form D filings
- Terrance KurtenbachExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 14 granted of 37- GrantedMethods Of Using Ultrasound Waves For Sonodynamic TherapyUSPTOUS 12,741,161
- PendingPatient Interface For Facilitating Non-invasive Acoustic DeliveryUSPTOApplication 19645607
- GrantedIncoherent Field Sonodynamic Therapy For Treating CancerUSPTOUS 12,623,094
Show all 37 patent records
- Methods Of Using Ultrasound Waves For Sonodynamic TherapySep 22, 2026 · US 12,741,161Granted
- Patient Interface For Facilitating Non-invasive Acoustic DeliverySep 10, 2026 · Application 19645607Pending
- Incoherent Field Sonodynamic Therapy For Treating CancerMay 12, 2026 · US 12,623,094Granted
- Methods Of Sonodynamic Treatment Using UltrasoundApr 16, 2026 · Application 19320368Pending
- Ultrasound Arrays For Enhanced Sonodynamic Therapy For Treating CancerJan 22, 2026 · Application 19343971Pending
- Ultrasound Arrays For Enhanced Tissue TherapyNov 13, 2025 · Application 18868081Pending
- Ultrasound Arrays For Enhanced Sonodynamic Therapy For Treating CancerSep 30, 2025 · US 12,427,345Granted
- Methods Of Treating Cancer With DrugsApr 17, 2025 · Application 18919841Pending
- Methods Of Treating Cancer With DrugsNov 12, 2024 · US 12,138,488Granted
- Incoherent Field Sonodynamic Therapy For Treating CancerSep 24, 2024 · US 12,097,392Granted
- Systems And Methods Of Non-invasive Sonodynamic TherapySep 5, 2024 · Application 18656122Pending
- Systems And Methods Of Using Acoustic Waves For Non-invasive Sonodynamic TherapyAug 22, 2024 · Application 18648807Pending
- Methods Of Using Ultrasound Waves For Sonodynamic TherapyJun 27, 2024 · Application 18411849Pending
- Methods Of Producing Randomized Ultrasound Waves For Sonodynamic TherapyMay 14, 2024 · US 11,980,777Granted
- Methods Of Using Planar Or Defocused Acoustic Waves For Non-invasive Sonodynamic TherapyMay 7, 2024 · US 11,975,156Granted
- Blood Brain Barrier Penetration To Treat GlioblastomaJan 25, 2024 · Application 18040610Pending
- Methods Of Using Ultrasound Waves For Sonodynamic TherapyJan 16, 2024 · US 11,872,414Granted
- Methods Of Treating Tumors With DrugsJan 9, 2024 · US 11,865,372Granted
- Methods Of Using Focused Acoustic Waves For Non-invasive Sonodynamic TherapyOct 26, 2023 · Application 18214421Pending
- Ultrasound Arrays For Enhanced Sonodynamic Therapy For Treating CancerOct 26, 2023 · Application 18215515Pending
- Methods Of Using Planar Acoustic Waves For Non-invasive Sonodynamic TherapyAug 22, 2023 · US 11,730,980Granted
- Zero Vergence Ultrasound Waves For Sonodynamic TherapyAug 15, 2023 · US 11,724,132Granted
- Methods Of Treating Tumors With Pro DrugsJul 20, 2023 · Application 18125971Pending
- Methods Of Treating Tumors With Pro DrugsApr 4, 2023 · US 11,617,904Granted
- Zero Vergence Ultrasound Waves For Sonodynamic TherapyNov 8, 2022 · US 11,491,353Granted
- Methods Of Treating Tumors With Pro DrugsMay 3, 2022 · US 11,318,332Granted
- Tissue Treatment With Sensitizer And Light And/or SoundAug 5, 2021 · Application 17266157Pending
- Device And Method For Use Of Photodynamic TherapyJan 14, 2021 · Application 16861622Pending
- Ultrasound Arrays For Enhanced Tissue TherapyApplication PCTUS2023023558Pending
- Ultrasound Arrays For Enhanced Sonodynamic Therapy For Treating CancerApplication PCTUS2021071101Pending
- Non-invasive Sonodynamic TherapyApplication PCTUS2020017983Pending
- Ensonification Drive Patterns For Sonodynamic TherapyApplication 63062879Pending
- Ultrasound Arrays For Enhanced Tissue TherapyApplication 63346192Pending
- Sonodynamic Therapy Methods And Systems For Treating CancerApplication 63062915Pending
- Sonodynamic Therapy Methods And Systems For Treating CancerApplication 63062926Pending
- Enhanced Sonodynamic TherapyApplication 63062937Pending
- Ultrasound Arrays For Initiating Sonodynamic TherapyApplication 63062895Pending
Related companies, and why
- Ankyra Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Checkpoint Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Longboard Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- IN8BIO, INC.Similar federal contract value in Biotech · null in contracts
- Convergent TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Amylyx Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .